Robot Cuts Skin Cancer Screening Time to Minutes

Imagine getting a complete skin cancer screening in just minutes instead of waiting months for an appointment. That future just got $18 million closer to reality.

SquareMind, a medical robotics company, secured major funding to launch Swan, a robot that performs full-body skin exams using artificial intelligence. The platform captures detailed images of every inch of skin in a single quick session, giving dermatologists the data they need to spot potentially deadly melanomas early.

The timing couldn't be better. Dermatologists are drowning in demand as aging populations seek more skin care, with appointment waitlists now stretching several months. Skin screenings are the most common procedure in dermatology, but time-pressed doctors struggle to document everything thoroughly during rushed appointments.

That documentation gap matters enormously. Eighty percent of melanomas, one of the most lethal skin cancers, are brand new lesions. Without detailed records of what someone's skin looked like before, catching these new spots becomes much harder.

Swan changes the game by automating the imaging process. Patients stand in a private exam room while the robotic arm moves around them, guided by visual and audio prompts. The experience is contactless and comfortable, and the whole session takes just minutes.

The robot captures standardized images at the same detail level doctors typically see when examining individual moles up close, but across the entire body. AI software then helps physicians review the images and track changes over time, though doctors maintain complete clinical judgment on all decisions.

The Ripple Effect

The investment round was led by Sonder Capital, co-founded by Fred Moll, the pioneer behind Intuitive Surgical's groundbreaking medical robots. Additional backing came from the French government's Deeptech 2030 Fund and several other venture partners who see potential for Swan to become the global standard in modern dermatology.

SquareMind developed Swan in collaboration with leading dermatologists who understood firsthand the crushing cognitive load and fatigue their colleagues face. The company envisions the robot as a companion that reduces burden and optimizes time, letting physicians focus on patient care instead of administrative documentation.

The funding will help SquareMind grow its commercial, engineering, and customer support teams as they prepare for launch. With strong interest already coming from practices and hospitals on both sides of the Atlantic, the company is positioning itself to meet surging demand.

For patients worried about suspicious moles but facing months-long waits, and for dermatologists struggling to serve everyone who needs care, this robotic assistant represents a genuine breakthrough in making lifesaving screenings faster and more accessible.